Phenelzine
Brand names: Nardil
Phenelzine is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) used in the treatment of depression, including atypical and treatment-resistant cases.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It irreversibly inhibits monoamine oxidase, increasing central availability of serotonin, noradrenaline and dopamine; restoration of enzyme activity requires synthesis of new monoamine oxidase.
Prescribing in practice
- Patients must avoid tyramine-rich foods and sympathomimetic or serotonergic drugs because of the risk of severe hypertensive crisis (the 'cheese reaction') and serotonin syndrome.
- Adequate washout periods are required when switching to or from other antidepressants, including a longer interval after stopping fluoxetine.
- Postural hypotension, insomnia and hepatotoxicity may occur, and abrupt withdrawal should be avoided.
Monitoring
Monitor blood pressure, mental state and liver function, and remain alert for signs of hypertensive crisis or serotonin toxicity.
Counselling the patient
- You will be given a list of foods and medicines to avoid, including mature cheese, cured meats and yeast extracts; follow it carefully.
- Tell any healthcare professional or pharmacist that you take a MAOI before starting any new medicine, including over-the-counter remedies.
- Seek urgent help if you develop a severe throbbing headache, palpitations or chest pain.
Evidence & guidelines
The dietary and drug interaction precautions for irreversible MAOIs such as phenelzine are well established and reinforced by MHRA and SPC guidance.
Reference: Maudsley Prescribing Guidelines (13th Ed); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185